- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02145533
Matrix Metalloproteinases (MMPs),Neutrophil Gelatinase-associated Lipocalin (NGAL) Tissue and Plasma Levels and Aneurysms
Evaluation of Plasma and Tissue Levels of Metalloproteinases and Neutrophil Gelatinase-associated Lipocalin in Arterial Aneurysms.
An association between arterial aneurysms and matrix metalloproteinases (MMPs) has been described previously. MMPs regulate extracellular structural proteins and tissue remodeling. Neutrophil Gelatinase-associated Lipocalin (NGAL) is involved in the regulation of MMP activity. The aim of this work was to study the relationship between the levels of MMPs and NGAL and arterial aneurysms.
In a multicenter, open label, parallel groups, prospective study, patients with aneurysmal disease were divided into two groups: Group I (with ruptured aneurysm) and Group II (with non-ruptured aneurysm). Healthy volunteer patients were also enrolled and represented the control group (Group III).
The investigators enrolled 307 patients (Group I: 107, Group II: 200) with arterial aneurysm: 49 popliteal, 31 common femoral, 2 superficial femoral, 29 common iliac artery, 3 common carotid and 193 abdominal aorta. Finally, 11 healthy volunteer patients (9 males and 2 females, age range 40-70 year-old, median 56) were enrolled in Group III.
Elisa test and Western blot analysis revealed greater levels of immunoreactive MMP-9 and NGAL in all patients with ruptured aneurysms, both central and peripheral aneurysms, and in the aneurismal vessels.
These results provide important advances in the understanding of the natural history of arterial aneurysms. MMPs and NGAL play a role in development of arterial aneurysms and they may represent molecular markers for the prevention of aneurysmal rupture
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Catanzaro, Italy, 88100
- University of Catanzaro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with the diagnosis of arterial aneurysmal disease
Exclusion Criteria:
- History of cancer
- Hepatic failure
- Infectious or autoimmune diseases
- Patients requiring endovascular treatment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Group I
patient with ruptured aneurysms
|
|
Group II
patients with non-ruptured aneurysms
|
|
Group III
Healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of MMPs levels in ruptured and non-ruptured aneurysms
Time Frame: 52 months
|
MMPs plasma levels are evaluated via ELISA test.
MMPs tissue levels are evaluated via Immunoblotting using anti MMPs monoclonal antibodies
|
52 months
|
|
Evaluation of NGAL levels in ruptured and non-ruptured aneurysms
Time Frame: 52 months
|
NGAL plasma levels are evaluated via ELISA test.
NGAL tissue levels are evaluated via Immunoblotting using anti NGAL monoclonal antibodies
|
52 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Stefano de Franciscis, M.D., University Magna Graecia of Catanzaro
- Principal Investigator: Raffaele Serra, University Magna Graecia of Catanzaro
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SURVAS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MMPs and NGAL in Ruptured and Non-ruptured Aneurysms
-
Wilhelminenspital ViennaRecruitingSymptomatic Non-ruptured Abdominal Aortic AneurysmsAustria
-
Galaxy Therapeutics INCCompletedAneurysm | Aneurysm, Ruptured | Aneurysms SaccularColombia
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Fondation Ophtalmologique Adolphe de RothschildActive, not recruitingIntracranial Aneurysms | Ruptured AneurysmFrance
-
UMC UtrechtPhilips Medical Systems; University Medical Center Hamburg-Eppendorf (UKE); AP-HP...Active, not recruitingIntracranial Aneurysms | Unruptured Intracranial Aneurysm | Subarachnoid Hemorrhage (SAH) From Ruptured AneurysmNetherlands
-
Shape Memory Medical, Inc.CompletedRuptured or Unruptured Cerebral AneurysmsChile
-
Microvention-Terumo, Inc.Semmes-Murphey FoundationActive, not recruiting
-
University of BolognaCompletedThoracoabdominal Aortic Aneurysm | Ruptured Thoracic Aneurysm | Ruptured Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm, RupturedItaly
-
Louisiana State University, Baton RougeLouisiana State University Health Sciences Center in New Orleans; Clinical... and other collaboratorsCompletedEvidence of Ruptured Membranes in Women Greater Than 15 WeekdUnited States
-
Zhujiang HospitalSecond Affiliated Hospital, School of Medicine, Zhejiang University; Xuanwu... and other collaboratorsUnknownUnruptured Intracranial Aneurysms | Ruptured Intracranial Aneurysms | Stent-Assisted Coiling | Non-Stent-Assisted Coiling | Craniotomy ClippingChina